Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double Blind Study of Safety and Reduction in Signs and Symptoms During Treatment With Tocilizumab Versus Placebo, in Combination With DMARD Therapy, in Patients With Active Rheumatoid Arthritis and Inadequate Response to Current DMARD Therapy

NCT00773461 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT00773461
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00773461 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double Blind Study of Safety and Reduction in Signs and Symptoms During Treatment With Tocilizumab Versus Placebo, in Combination With DMARD Therapy, in Patients With Active Rheumatoid Arthritis and Inadequate Response to Current DMARD Therapy
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2008
Completion date
July 22, 2010
Enrollment
209 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis